Stock 6446 PHARMAESSENTIA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages PharmaEssentia Corporation

Equities

6446

TW0006446008

End-of-day quote Taiwan S.E.
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
285.5 TWD -1.04% Intraday chart for PharmaEssentia Corporation 0.00% -17.49%
26/04 PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA CI
24/04 PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon Alfa-2b) for PV in Brazil
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia
Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B for the Treatment of PV in China
PharmaEssentia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
PharmaEssentia Corporation announces an Equity Buyback for 4,000,000 shares, for TWD 8,846.64 million.
PharmaEssentia Corporation authorizes a Buyback Plan.
PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV)
PharmaEssentia Corporation Selects Pint-Pharma as Commercial Partner for Besremi® (Ropeginterferon Alfa-2B-Njft) in Latin America
PharmaEssentia Corporation announces an Equity Buyback for 5,000,000 shares, representing 1.47% for TWD 8,846.64 million.
PharmaEssentia Corporation authorizes a Buyback Plan.
PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6446 Stock
  4. News PharmaEssentia Corporation
  5. Other languages